19
Jan
2018
Celgene’s Rumored Juno Talks, Hospitals Shoot at Generic Drugmakers, & Keytruda Hits a Phase III
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
Jan
2018
Reverse Engineering I-O Bispecifics for Autoimmunity, Pandion Snags $58M
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Jan
2018
Getting a Seat at the Table: The Long Run Podcast With Abbie Celniker
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Jan
2018
Celgene Gets a JAK2 for $1.1B, Novo Bids for Ablynx & Pfizer Drops Neuro: Pre#JPM18 Wrap
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Jan
2018
Spark Sets $850K Bar, Microsoft’s Bet on AI for Immune Mapping, & Startup Financings Galore
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Jan
2018
Microsoft Makes Nine-Figure Bet on Adaptive’s TCR-Antigen Map; BioNTech Hauls in $270M for 10-Drug Cancer Pipeline
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Jan
2018
Scholar Rock, After a Year on Pause, Snags $47M to Take New Tack Against SMA
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Jan
2018
Finding a Path in Biotech VC: The Long Run Podcast With Bob More
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
21
Dec
2017
How Did BioMarin Make It? The Long Run Podcast With Daniel Levine & Dan Maher
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Dec
2017
Five Things That I Think I Know About (My) Happiness
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
Dec
2017
Walk & Talk With Me on Powell Street at #JPM18
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Dec
2017
A16Z Rakes in New $450M Fund to Build ‘Engineering Biology’ Plays
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Dec
2017
Accelerator, Backed by Corporate VCs, Spreads Wings – But Not in Boston & SF
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Dec
2017
Biotech’s Test: Root for a Tax Windfall Or Support the Next Generation of Scientists?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Dec
2017
Sage Crushes Depression Trial, Spark’s Hemophilia Tour de Force, & CVS-Aetna Megadeal
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Dec
2017
Obsidian Therapeutics Gets $49.5M to Bring CAR-T Dosing Under Control
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Dec
2017
The Long Run Podcast: Steve Graham on Racism in Corporate America
Steve Graham is today’s guest on The Long Run podcast. Chances are you don’t know his name, but Graham is a major behind-the-scenes player in biotech. Graham is the co-chair of the life sciences practice at the law firm Fenwick & West, and managing partner of the firm’s Seattle office. He has been working with biotech boards, handling corporate law,... Read More
6
Dec
2017
“You Went to SITC and All You Got Was This TR Post? (Part 2)
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Dec
2017
The Microbiome: New Technology, Commercial Challenges, and Opportunities
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
Dec
2017
Foundation Medicine Wins FDA/CMS Two-Fer, Azar Calls Out High Drug Prices & Biogen Buys MS Challenger
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.